J&J’s IL-23 star guselkumab grabs the spotlight in PhIII psoriasis showdown
J&J has long had high hopes for its anti-inflammatory IL-23 drug guselkumab. And today in Vienna they detailed the first round of Phase III data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
